10X Genomics faced a significant decline in its stock price, dropping over 17% in a single trading session.
10X Genomics Inc (NASDAQ:TXG) saw its stock price fall sharply yesterday, closing down 17.47% at CA$80.66. This drop came despite the company announcing promising developments in its spatial biology platform, Atera.
Investor takeaway: Investors should be cautious as the sharp decline in 10X Genomics' stock raises concerns about market sentiment and potential underlying issues affecting the company's growth trajectory.
Advertisement
10X Genomics Inc
TXG.US
TXG.US
10X Genomics Inc
WealthAwesomeMarket cap
$9.85B
52W high
$102.81
52W low
$12.34
1W change
+3.41%
Beta
1.99
Analyst Price Targets
Based on 19 analysts covering TXG · as of Oct 15, 2026
Wall Street analysts forecast TXG stock price to rise 4.0% over the next 12 months.
Consensus
Buy3.68 / 5.00
Avg. Target
C$77.00
+4.0% Upside
Previously C$75.67 on Oct 14, 2026
Current Price
C$74.04
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TXG's historical volatility
30-Day Vol
90.2%
Annualized
90-Day Vol
79.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$83.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$74.03 | C$54.22 – C$101.07 |
| 60 trading days | C$78.57 | C$50.59 – C$122.03 |
| 90 trading days | C$83.39 | C$48.63 – C$142.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
The company has a strong product pipeline and significant demand for its Atera platform. If market conditions stabilize, this could lead to future growth.
Bear case
The recent drop in stock price suggests that investor confidence may be wavering. This could be due to broader market pressures or company-specific challenges that need to be addressed.
Market Reaction to Atera's Launch
Despite the initial excitement surrounding Atera's launch, which was expected to boost growth, the market reacted negatively. Investors seem to be questioning whether demand for Atera can sustain the company's valuation, especially with rising operational costs and competitive pressures.
Advertisement
Broader Market Trends Impacting TXG
The decline in 10X Genomics' stock reflects broader market trends. Rising Treasury yields and increased borrowing costs have made investors wary of growth stocks. This shift in sentiment could be impacting companies like 10X Genomics that are still in the growth phase and not yet profitable.
Future Prospects and Investor Sentiment
Looking ahead, 10X Genomics needs to show it can turn the initial demand for Atera into sustainable revenue growth. The company's future performance will likely depend on how well it navigates current market challenges and reassures investors about its long-term potential.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
